1. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Issue 3 (March 2022) Authors: Sutharsan, Sivagurunathan; McKone, Edward F; Downey, Damian G; Duckers, Jamie; MacGregor, Gordon; Tullis, Elizabeth; Van Braeckel, Eva; Wainwright, Claire E; Watson, Danie; Ahluwalia, Neil; Bruinsma, Bote G; Harris, Christopher; Lam, Anna P; Lou, Yiyue; Moskowitz, Samuel M; Tian, Simon; Yuan, Jas... Journal: Lancet Issue: Volume 10:Issue 3(2022) Page Start: 267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗